How European Biopharmas Can Benefit From Establishing A U.S. Presence

By Rami Levin

The United States does not have a monopoly on biopharma innovation – biotech companies are forming all over the world to advance scientific breakthroughs and address unmet needs. However, the maturity and scale of the biotech industry in the U.S. can offer several competitive advantages, making expansion into the U.S. well worth considering for leaders of biopharma companies formed in other countries, such as across Europe. As the current CEO of Copenhagen-based rare disease company Saniona, and as former president of the North American business for Swedish pharmaceutical company Sobi, I have now twice had the experience of building a U.S. presence for a European biopharma company, gaining many insights along the way.